Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Established industries often operate like cartels with unwritten rules, such as avoiding aggressive marketing. New entrants gain a significant edge by deliberately violating these norms, forcing incumbents to react to a game they don't want to play. This creates differentiation beyond the core product or service.

A company can build a significant competitive advantage in healthcare by deliberately *not* touching or seeing Protected Health Information (PHI). Focusing exclusively on metadata reduces regulatory overhead and security risks, allowing the business to solve the critical problem of data orchestration and intelligence, a layer often neglected by data aggregators.

The pharmaceutical industry is often misunderstood because it communicates through faceless corporate entities. It could learn from tech's "go direct" strategy, where leaders tell compelling stories. Highlighting the scientists and patient journeys behind breakthroughs could dramatically improve public perception and appreciation.

The book draws a parallel between the behavior of serial killers and the Asarco corporation, which deliberately concealed research, lied to the public, and performed cost-benefit analyses on lead-poisoned children. This frames corporate malfeasance not just as unethical, but as a form of institutional psychopathy.

Extremist figures are not organic phenomena but are actively amplified by social media algorithms that prioritize incendiary content for engagement. This process elevates noxious ideas far beyond their natural reach, effectively manufacturing influence for profit and normalizing extremism.

Selling low-cost vaccines to organizations like Gavi isn't just charity for pharmaceutical companies. It creates massive economies of scale, lowering the cost of goods for their high-margin primary markets and increasing overall net profit, creating a powerful win-win incentive structure.

Modern advertising weaponizes fear to generate sales. By creating or amplifying insecurities about health, social status, or safety, companies manufacture a problem that their product can conveniently solve, contributing to a baseline level of societal anxiety for commercial gain.

Unlike labor-dependent services that get more expensive, prescription drugs offer a unique societal ROI because they eventually go generic and become cheaper. This deflationary aspect is a powerful, underappreciated argument for investing in drug development, as successful medicines provide compounding value to society over time.